Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A and ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...

The trimeric pre-fusion glycoprotein F is essential for accurately assessing the immunogenicity of RSV vaccines. We strictly adhere to ... whether it comes through recombinant proteins, antibodies, ...

Both RSV and hMPV cause respiratory disease in people with weaker immune systems, such as the elderly. The Molecular Clamp platform stabilises viral glycoprotein antigens in a 'pre-fusion' state ...

The fusion between Swedish pharmaceutical ... including several different approaches towards Hepatitis C and Respiratory Syncytial Virus (RSV). It was around this point that AZ decided to re ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

In the current study, people with a history of infections also had changes to 260 immune-related proteins out of ... also recommends the Respiratory Syncytial Virus (RSV) vaccine for everyone ...

being RSV 604, a benzodiazepine that targets the nucleocapsid protein of RSV. [22] Rhinovirus infections (the common cold), despite their socioeconomic impact, have received (surprisingly ...